Latest Clinical Trials News

Imugene's azer-cel therapy shows a third patient response in the BTKi combination cohort of its Phase 1b trial, while CEO Leslie Chong steps down after nearly 11 years, prompting a leadership search.

Syntara secured positive FDA feedback for its Phase 2b amsulostat trial in myelofibrosis and raised $8 million to extend its cash runway to Q3 2027, while preliminary data showed promising brain inflammation reduction in a Parkinson’s-related disorder.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

Resonance Health (ASX:RHT) closed FY26 with a net operating cash inflow of $2.9 million and completed recruitment for a $13.8 million clinical trial, underpinning a robust contract pipeline and growing net cash position.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Radiopharm Theranostics (ASX: RAD) has requested an immediate voluntary suspension of its shares pending a material capital raising announcement expected before markets open on 27 July 2026.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Dimerix has strengthened its kidney disease pipeline with a US patent grant for DMX-652, extending protection until 2043 and setting the stage for a Phase 2 trial targeting acute kidney injury after cardiac surgery.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.